Market revenue in 2023 | USD 359.9 million |
Market revenue in 2030 | USD 622.6 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Kits |
Fastest growing segment | Assays |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Kits, Assays |
Key market players worldwide | Myriad Genetics Inc, Ambry Genetics, Thermo Fisher Scientific Inc, Illumina Inc, Centogene NV Ordinary Shares, Amoy Diagnostics, Invitae Corp, NeoGenomics, Qiagen NV, Agilent Technologies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to parp inhibitor biomarkers market will help companies and investors design strategic landscapes.
Kits was the largest segment with a revenue share of 65.35% in 2023. Horizon Databook has segmented the U.S. parp inhibitor biomarkers market based on kits, assays covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. parp inhibitor biomarkers market, including forecasts for subscribers. This country databook contains high-level insights into U.S. parp inhibitor biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account